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An  assessment  of genotoxicity  is  a precondition  for marketing  authorization  respectively  registration  of
herbal  medicinal  products  (HMPs),  as well  as  for inclusion  into  the  ‘Community  list of  herbal  substances,
preparations  and  combinations  thereof  for  use  in  traditional  herbal  medicinal  products’  established  by
the  European  Commission  in  accordance  with  Directive  2001/83/EC  as amended,  and based  on  proposals
from  the  Committee  on  Herbal  Medicinal  Products  (HMPC).
In  the ‘Guideline  on the assessment  of  genotoxicity  of  herbal  substances/preparations’
(EMEA/HMPC/107079/2007)  HMPC  has described  a  stepwise  approach  for genotoxicity  testing,  according
to  which  the  Ames  test  is  a  sufﬁcient  base  for the assessment  of genotoxicity  in  case  of  an  unequivocally
negative  result.  For  reducing  efforts  for testing  of individual  herbal  substances/preparations,  HMPC  has
also developed  the ‘guideline  on  selection  of test  materials  for  genotoxicity  testing  for traditional  herbal
medicinal  products/herbal  medicinal  products’  (EMEA/HMPC/67644/2009)  with  the  aim to  allow  testing
of a standard  range  of test  materials  which  could  be considered  representative  of  the commonly  used
preparations  from  a  speciﬁc  herbal  drug  according  to  a ‘bracketing/matrixing’  approach.
The  purpose  of this  paper  is to provide  data  on  the  practical  application  of  this  bracketing  and  matrixing
concept  using  the  example  of Valerianae  radix,  with  the  intention  of facilitating  its  inclusion  in  the  “Com-
munity  list”.  Five  extraction  solvents,  representing  the extremes  of  the  polarity  range  and  including  also
mid-range  extraction  solvents,  were  used,  covering  the  entire  spectrum  of  phytochemical  constituents
of  Valerianae  radix, thereby  including  polar  and  non-polar  constituents.  Extracts  were  tested  in the  Ames
test  according  to  all  relevant  guidelines.  Results  were  unequivocally  negative  for  all  extracts.  A review
of  the  literature  showed  that this  result  is in accordance  with  the  available  data,  thus  demonstrating  the
lack  of  a genotoxic  potential.
In  conclusion  the two guidelines  on genotoxicity  provide  a practically  applicable  concept.  Valerianae
radix  has no  genotoxic  potential,  supporting  its use  in  HMPs  and  its  inclusion  in  the  Community  list.
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2004/24/EC. According to regulation (EC) No 726/2004, the com-
mittee for herbal medicinal products (HMPC) is responsible for
preparing the view of the European Medicines Agency (EMA,
formerly EMEA) on herbal medicines (Knöss and Chinou 2012).
According to the guideline EMEA/HMPC/32116/2005, for many
herbal substances and preparations, used in well-established or
traditional herbal medicinal products (HMPs), a safety proﬁle in
accordance to modern standards is supported or at least partially
substituted by their documented history of medicinal use. Thus,
only if a safety concern is recognized or suspected, supporting
non-clinical investigations may  be needed (EMEA, 2008). In gen-
eral, the combination of documented experience gained during
le under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Table 1
Test materials used for genotoxicity testing of Valeriana ofﬁcinalis L., radix.
Extraction medium DER Native extract Excipients
Watera 3–6:1 70% 30%
Ethanol 40% (V/V)a 4–7:1 80% 20%
Ethanol 70% (V/V)a 3–6:1 80% 20%
Ethanol 96% (V/V)a 1:10 n.a. (oily macerate) Rapeseed oil
Heptaneb 167:1 100% 0%
n.a. not applicable; DER drug extract ratio.
a Extract contained in a HMP  registered or authorized within the EU.
b Extract especially prepared (by two-step mazeration with stirring at 45 ◦C) for
taneously or by the action of the test chemical) will continue to
divide and to form colonies, thereby indicating a concentration-
related mutagenic effect of the test item. The testing of the
extracts from valerian root was conducted by LPT (Laboratory of
Table 2
Chemicals used as positive control items.
(a) Without metabolic activation
Sodium azide in H2O (10 g/plate) TA 1535, TA 100
2-Nitro-ﬂuorene in DMSO (10 g/plate) TA 98
9-Aminoacridine in ethanol abs. (100 g/plate) TA 1537
Methyl-methane sulfonate (MMS)  in DMSO
(1300 g/plate)
TA 102O. Kelber et al. / Phytom
ong-standing use with bibliographic data is the main basis of the
on-clinical assessment of traditional and well-established HMPs.
herefore, particular attention should be paid to effects that are
ifﬁcult or even impossible to detect clinically. They include geno-
oxicity, carcinogenicity, and toxicity to reproduction. Especially
he lack of data from genotoxicity testing may  present a safety
oncern. Thus there is a need for the assessment of the genotoxic
otential of herbal preparations. For many active substances data
n genotoxicity are missing or data described in the literature are
nadequate. If an adequate assessment cannot be made, further
enotoxicity testing is required (EMEA, 2006b).
Guidelines on genotoxicity testing of pharmaceuticals, pri-
arily directed to the assessment of new chemically deﬁned
ctive ingredients, have been established by ICH since the
990s (ICH S2) and have been adopted as EMA  guideline
EMA/CHMP/ICH/126642/2008). This guideline describes a battery
pproach of genotoxicity testing, in which pro- and eukaryotic test
ystems in in vitro and in vivo are employed (EMEA, 2008). The basic
equirement is to assess genotoxicity initially in a bacterial reverse
utation test, followed by tests in mammalian cells in vitro and a
andatory test in a mammalian model in vivo.
For HMPs, the HMPC has established a stepwise approach, in
rder to address both scientiﬁc aspects of genotoxicity testing and
he special needs of HMPs within the current regulatory framework.
his approach also includes the documented history of medicinal
se, with the guideline EMEA/HMPC/32116/2005 setting the frame
nd the guideline EMEA/HMPC/107079/2007 giving detailed guid-
nce. The basic assessment is a bacterial reverse mutation test,
sing a battery of different strains as well as metabolic activation.
or technical information on how to perform this test (Ames-test;
almonella typhimurium mutation assay) the OECD guideline no.
71 (OECD, 1997a) is referred to. Only in cases of equivocal or
ositive results, which cannot be explained sufﬁciently or clearly
ttributed to speciﬁc constituents with a well-known safety proﬁle
e.g. the ubiquitous quercetin or other ﬂavonoids common also in
ood), additional in vitro tests, e.g. mouse lymphoma cell assay, and,
f necessary, also in vivo studies are required.
Usually, European community herbal monographs established
y the HMPC for well-established and/or traditional use cover a
ange of herbal preparations. In order to alleviate the manufac-
urers task of testing their own speciﬁc preparations, a distinct
uidance was developed offering a strategy to reduce the num-
er of test materials (EMEA, 2009). This approach suggests testing
 representative range of preparations of an herbal drug rather
han conducting individual tests as is otherwise required – the so-
alled ‘bracketing/matrixing’ approach (Wiesner and Knöss, 2010).
he main objective of this guideline is to achieve consensus on a
tandard range of test materials which could be considered rep-
esentative of the commonly used preparations of a herbal drug,
ith the intention to facilitate providing data necessary for allow-
ng their entry to the Community list established by decision of the
uropean Commission (2008/911EC).
This guideline mentions the option to extrapolate the results
btained with a speciﬁc preparation to closely related preparations.
nly in case of extracts prepared with ethanol/water mixtures of
ubstantially different concentrations, the demonstration of the
hytochemical similarity of the test materials may  be required
EMEA, 2009). This test design also assumes that the genotoxic
otential of any intermediate preparation is represented by the
esults of the extremes tested.
Recently, the conduction of a joint project for testing geno-
oxicity of selected extracts using this “bracketing and matrixing”
oncept for more than 30 herbal drugs has been reported (Gaedcke
t al., 2009; Kelber et al., 2012). The present paper shows the
esults of the practical application of the “bracketing and matrix-
ng” concept on a speciﬁc herbal drug, Valerianae radix. Thecoverage of the non polar extractables, not contained in an HPM registered or autho-
rized within the EU, and containing valepotriates (isovaltrate 1.35%, valtrate 0.76%,
measured by HPLC).
community herbal monograph from October 2006 on Valerianae
radix lists a wide range of preparations, covering extracts prepared
with ethanol/water (ethanol max. 40–70% (V/V)), dried valerian
root (powdered herbal substance), aqueous dry extracts, valerian
(ethanolic) tincture, expressed juice and valerian root oil (EMEA,
2006a).
Materials and methods
Selection of extracts
Extracts from valerian root used as active substances in
HMPs authorized or registered within the EU were provided by
pharmaceutical manufacturers. The extracts had been produced
and characterized analytically in compliance with speciﬁcations
approved by regulatory agencies and the respective regulatory
guidelines. Extract characteristics have been documented in accor-
dance with the respective certiﬁcates of analysis. Table 1 shows ﬁve
different extracts that were used in the genotoxicity assessments.
They were selected according to the principles of the guideline
EMEA/HMPC/67644/2009 (EMEA, 2008) and represent the com-
plete range of extraction solvents including water as the most polar
and heptane as the most apolar solvent. They also included extracts
of intermediate strength, prepared with ethanol 40% (V/V) and 70%
(V/V) as well as an oily macerate prepared on the basis of ethanol
96% (V/V). Thus they are assumed to cover the whole phytochemical
range of preparations of valerian root (Table 1).
Reverse mutation test
The Salmonella typhimurium histidine (his) reverse mutation test
is a microbial assay which measures his− → his+ reversion induced
by chemicals which cause base changes or frameshift mutations
in the genome of this organism (Ames et al., 1973, 1975). Only
bacteria that have reverted to histidine-independence (either spon-(b) With metabolic activation
2-Aminoanthracene in DMSO (2 g/plate) TA 98, TA 102, TA 1537
Cyclophosphamide in aqua ad iniectabilia
(1500 g/plate)
TA 100, TA 1535
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Table 3
Range of spontaneous reversion frequencies (negative reference item). Spontaneous
reversion frequencies may  be slightly different on plates with S9 mix and vary
slightly from experiment to experiment.
TA 98 20–60
TA 100 100–200
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Table 5
Overview of the results of mutagenicity testing of root extracts from Valeriana
ofﬁcinalis L., in ﬁve strains of S. typhimurium. All native extracts were tested up
to  5000 g/plate, the highest concentration according to current guidelines. The
respective positive controls showed mutagenicity as expected.
Extraction medium TA 98 TA 100 TA 102 TA 1535 TA 1537
Water None None None None None
Ethanol 40% (V/V) None None None None None
Ethanol 70% (V/V) None None None None None
T
P
v
NTA 102 240–320
TA 1535 10–35
TA 1537 3–20
harmacology and Toxicology, Hamburg, Germany) according
o the relevant OECD guideline, No. 471, and in compliance
ith the EC directive on methods for the determination of
oxicity–mutagenicity (European Commission, 2000), the ICH
uideline S2 (R1) (EMA, 2012), and to good laboratory practice
GLP) regulations (German Chemicals Act and OECD, 1998). Also
he US FDA GLP regulations (FDA, 2012) and the Japanese guide-
ines for non-clinical studies of drugs manual (Japanese Ministry of
ealth and Welfare, 1995) were considered.
According to these guidelines, 5 strains of Salmonella
yphimurium obtained from Dr. Bruce N. Ames were used,
fter check on genetic identity. These strains were TA 98 and TA
537, which primarily respond to frameshift mutagens, and TA
00, TA 102 and TA 1535, which respond to base-pair substitution
utagens. These strains contain, in addition to the mutation in
he histidine operon, several other mutations which increase their
ensitivity against mutagens. Extracts were tested in amounts
f 100, 316, 1000, 3160 and 5000 g native extract per plate,
ith half-logarithmic intervals between concentrations and with
riplicates for each concentration and experiment. Two indepen-
ent experiments, each with and without metabolic activation,
ere conducted: the ﬁrst experiment was carried out with the
tandard plate incorporation method, the second one with the
re-incubation method (OECD, 1997a).
olvents, reference items, metabolic activation system
Shortly before use, extracts were dissolved in dimethylsulfoxide
DMSO). The vehicle served as negative control. Preliminary to the
ain test, a cytotoxicity test was carried out as a plate incorpora-
ion test without metabolic activation, using strain TA 100 and the
rocedure described below. In the main test, the 5 different con-
entrations mentioned above were tested. Positive control items
ere selected according to guidelines (Table 2).
Post-mitochondrial fraction (S9 fraction) from rats treated with
roclor 1254 was prepared according to Maron and Ames (Maron
nd Ames, 1983). S9 was collected from 20 to 30 rats, character-
zed regarding protein and P 450content (Lowry et al., 1951; Mazel,
971) and stored in liquid nitrogen. The S9 mix  was  freshly pre-
ared on the day of the test (Maron and Ames, 1983), containing 5%
able 4
reliminary cytotoxicity testing with root extracts from Valeriana ofﬁcinalis L., in S. typhim
alues compared to NR point to a potential enhancement of revertant rates, reduced valu
Extraction medium
g/plate
Water Ethanol 40% 
5000 181.5 166.0 
3160  168.5 159.5 
1000  165.5 156.0 
316  189.5 140.0 
100  156.5 141.5 
31.6  156.0 142.5 
10.0  156.0 160.5 
3.16  167.0 164.5 
1.0  150.5 166.0 
0.316  136.5 156.0 
NR  178.0 158.5 
R = negative reference item/solvent control: DMSO, 100 l/plate.Ethanol 96% (V/V) None None None None None
Heptane None None None None None
S9, MgCl2, KCl, glucose-6-phosphate, NADP and phosphate buffer
(pH 7.4), and ﬁlter-sterilised by using a 0.45 m ﬁlter.
Plate incorporation and pre-incubation methods
For plate incorporation, the test components were mixed with
the soft agar and then immediately poured onto a coded minimal
glucose agar plate. Plates were inverted and placed in a dark 37 ◦C
incubator for 48–72 h. The revertant colonies on the test and control
plates were counted with a colony counter (Biocount 2000, Biosys),
and the presence of the background lawn resulting from the trace
of histidine added to the top agar was  conﬁrmed on all plates.
In the pre-incubation method, the test item/test solution was
pre-incubated with the test strain for 20 min  at 37 ◦C prior to mix-
ing with the overlay agar. The remaining steps were the same as
described for the plate incorporation method.
Toxicity was  evidenced by a reduction in the number of sponta-
neous revertants, a clearing or diminution of the background lawn
or by the degree of survival of the treated cultures. Insolubility of
the test item was  deﬁned as precipitation in the ﬁnal mixture under
the actual test conditions and evident to the unaided eye. The pre-
cipitate should not interfere with the scoring. Test items that were
cytotoxic already below 5 mg/plate or 5 l/plate were tested up to
a cytotoxic concentration.
Evaluation
While the statistical evaluation of the results of the Ames test
is under discussion (Kim and Margolin, 1999; Mortelmans and
Zeiger, 2000) and depends also from the historical data achieved
in the individual testing site, the responsible laboratory consid-
ered a test item showing a positive response, if the number of
revertants was  signiﬁcantly increased (p ≤ 0.05, U-test according
to Mann and Whitney, Colquhoun, 1971) (ranges see Table 3) to at
least 2-fold of the respective solvent control for TA 98, TA 100 and
TA 102 and 3-fold of the solvent control for TA 1535 and TA 1537
in both of the independent experiments. In addition, a signiﬁcant
urium strain TA 100. Values are given as revertants per plate. Signiﬁcantly increased
es to cytotoxicity.
Ethanol 70% Ethanol 96%/
oily mazerate
Heptan
151.5 119.0 124.0
153.0 150.5 115.5
188.5 131.0 119.0
177.0 159.5 122.0
160.5 121.0 139.5
168.5 123.5 133.5
123.5 128.5 125.5
141.0 143.5 134.5
154.5 119.0 115.0
155.0 136.5 154.5
174.0 124.0 155.0
O. Kelber et al. / Phytomedicin
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(p ≤ 0.05) concentration (log value)-related effect (Spearman’s rank
correlation coefﬁcient) had to be observed, and positive results had
to be reproducible. The histidine independence of the revertants
had to be conﬁrmed by streaking random samples on histidine-free
agar plates.
Cytotoxicity was  deﬁned as a reduction in the number of
colonies by more than 50% compared with the solvent control,
and/or a scarce background lawn.
Results
In the preliminary test, ten concentrations of the valerian
extracts under study ranging from 0.316 to 5000 g/plate were
tested. Signs of cytotoxicity were not noted (Table 4).
In the main study, ﬁve concentrations of each extract ranging
from 100 to 5000 g/plate were tested in independent experi-
ments, each carried out with and without metabolic activation.
Signs of cytotoxicity were not noted in both the plate incorpora-
tion test and the pre-incubation test up to the concentration of
5000 g/plate. A reduction in the number of colonies by slightly
more than 50% compared with the solvent control was noted in
strain TA 1537 without metabolic activation in the pre-incubation
test (aqueous extract) and plate incorporation test (extract with
ethanol 40% (V/V)), and with metabolic activation in the pre-
incubation test (aqueous extract) in higher concentrations, but was
rated by the laboratory as being coincidental, due to very low abso-
lute numbers of colonies and lack of a dose dependency.
A mutagenic effect (increase in revertant colony numbers as
compared to control counts) was  not observed for any of the vale-
rian extracts tested up to the concentration of 5000 g/plate in any
of the 5 test strains in two independent experiments with and with-
out metabolic activation (plate incorporation and pre-incubation
test, respectively), even if common regulatory thresholds of 2 (for
strains TA 98, TA 100, TA 1535 and TA 1537) or 1.5 (for strain TA
102) are taken into consideration. A summary of the results is given
in Table 5. The mean revertant rates are listed in Table 6.
According to guideline EMEA/HMPC/67644/2009 (EMEA, 2009),
the results cover the entire spectrum of phytochemical constituents
of valerian root, including polar and non-polar constituents, and
can therefore be considered representative of the commonly used
herbal substances/preparations prepared from it, including the
entire herbal drug. A negative test result fulﬁls the genotoxic-
ity testing requirements of directive 2001/83/EC and guideline
EMEA/HMPC/107079/2007 for including an herbal substance or
preparation in the Community list of herbal substances, prepa-
rations and combinations thereof if there are no other reasons
withstanding.
Discussion
The study follows current HMPC guidelines which aim to
provide a general framework and practical approaches on how
to assess or test the potential genotoxicity of herbal sub-
stances/preparations and how to interpret the results, thereby rep-
resenting a pragmatic approach to address both scientiﬁc aspects
of genotoxicity testing and the special needs of HMPs within the
current regulatory framework applicable to these products.
Due to the use of extraction solvents representing the extremes
of the polarity range and including also mid-range extraction sol-
vents, the entire spectrum of phytochemical constituents, including
polar and non-polar constituents, is covered. This allows also
the transfer of the results to further extracts with different drug
extract ratios, as relevant differences in the analytical proﬁle can
be assumed to be only due to a limited solubility of speciﬁc con-
stituents in the respective extraction solvent. The “bracketing and
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atrixing concept” warrants that also in case of such constituents
n optimal solvent has been included, thus making them accessible
o genotoxicity testing.
As the Ames tests were unequivocally negative (EMEA, 2008), on
he basis of the HMPC nonclinical guideline no further genotoxicity
esting of valerian root preparations is required (EMEA, 2006b). The
esults may  therefore facilitate the inclusion of valerian root and
reparations thereof in the Community list of herbal substances.
The lack of genotoxicity of valerian root seen in this study is
upported also by the available literature. This includes the ESCOP
onograph (ESCOP, 2003) as well as the assessment report of the
MPC (EMEA, 2007), which do not contain information pointing
o any relevant mutagenic properties of valerian root or prepa-
ations thereof. Within the latter, four publications have been
ssessed. In two earlier publications, data on alkylating, cytotoxic
nd mutagenic effects have been presented for valepotriates and
heir degradation products (Bos et al., 1998; von der Hude et al.,
986). However, these substances either are not detectable in vale-
ian root extracts contained in HMPs or are found only in very
ow amounts (Wagner and Jurcic, 1980). A further test was  con-
ucted in mice with a dietary product of undeﬁned quality. It
howed weak effects in the bone marrow micronucleus test in
 concentration of about 4 g/kg (Al-Majed et al., 2006), which is
uch higher than the recommended dosage in humans (6-fold of
he average human single dose calculated via human equivalent
ose for a 60 kg human) and is 2-fold of the highest dose level
pplicable for non-toxic substances in the mammalian erythrocyte
icronucleus test according to OECD (OECD, 1997b). A somatic
utation and recombination test in Drosophila melanogaster did
ot show any genotoxic effects of an infusion of valerian root.
s this drug had been purchased from a local health food store,
uestions concerning the quality of the herbal substance in rela-
ion to pharmaceutical properties and the dose used in therapy are
pen. In addition, this test procedure is not accepted as a stan-
ard method for the investigation of genotoxicity (Romero-Jimenez
t al., 2005).
Besides these publications, further studies are accessible via rel-
vant data bases (including Medline and Toxline). They include an
n vitro study with valepotriates in a human endothelial cell line
ECV304): With very high concentrations a moderate degree of
NA damage could be demonstrated in the Comet assay (Hui-Lian
t al., 2003). However, this was proven to be not due to muta-
enic properties of the substance, but to ROS-induced epigenetic
echanisms caused by the very high concentrations of test sub-
tance used. In addition, the test model is not yet validated. As
eing caused by epigenetic mechanisms and related to valepotri-
tes, which are not present in valerian preparations used in HMPs,
he results do not point to mutagenic properties relevant in ther-
py. In a further publication an herbal combination was assessed,
hich included a valerian dry extract and extracts from Crataegus
xyacantha and Passiﬂora incarnata (Tabach et al., 2009). Both the
esults of the Ames and the Micronucleus test did not indicate a
enotoxic potential.
Altogether, the literature data are in accordance with a lack
f genotoxic properties of preparations of Valeriana ofﬁcinalis
., and thereby also underline the validity of the genotoxic-
ty assessment conducted according to the HMPC guidelines
MEA/HMPC/340719/2005 and EMEA/HMPC/67644/2009.
This study therefore allows the conclusion that the framework
iven by HMPC in its guidelines mentioned above is apt to suc-
essfully generate data which may  support the inclusion of herbal
ubstances or preparations thereof in the Community list of herbal
ubstances as well as regulatory applications resp. registrations
f preparations from the respective herbal drugs. According to
MA/ICH-Guidelines the results have to be discussed when used
n marketing authorization procedures (EMEA, 2008).e 21 (2014) 1124–1129
Perspectives
The Application of the “Bracketing and Matrixing” approach to
further herbal substances/preparations seems to be very promising
for simplifying regulatory applications of HMPs in traditional or
well established medicinal use in Europe.
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